The main target of the Jerome Lejeune Foundation, a non-profit foundation, is research into genetic diseases with intellectual disability.

If you are a researcher investigating on Down syndrome and other intellectual disability from genetic origin appearing in early childhood, the Scientific Advisory Board of the Jerome Lejeune Foundation invites you to submit your research project aiming at deciphering the pathophysiology of the cognitive deficits of patients, especially those (up to 50% of the total amount of the global grant) with Down syndrome (trisomy 21) and linked pathologies as well as knowledge of the chromosome 21.


The calls for proposals have been changed!!


• Spring call for proposals will be dedicated to both Down syndrome and other rare intellectual disabilities from genetic origin such as Fragile X, cri du chat, Rett, Williams-Beuren, Prader-Willi, Angelman, Smith-Magenis and other syndromes, and will not exceed 50% of the total amount of the annual global grant. Autism not linked to above diseases is out of this call for grants.

Applications could cover fundamental, translational, epidemiological, clinical research, neurobiology, and pharmacology including animal pharmacology, genetic, genomic, iPSCs, and neuropsychology techniques or data analysis. Priority will be given to clinical research projects.

Two types of research projects may be submitted and will be separately evaluated by the scientific board experts or external reviewers if needed for each call:

• Advanced grants will be dedicated to larger breakthrough projects with preliminary data. The maximum funding will be 80,000.00 € for a maximum of two years (i.e. 40,000.00 € per year for a maximum of two years. Two to four projects could be funded per call.

• Pilot or exploratory grants will be dedicated to initial early stage experiments built on preliminary data, or to ancillary projects to primary larger projects.  The maximum funding will be 40,000.00 € for a maximum of two years (i.e. 20,000.00 € per year for a maximum of two years. The number of funded projects will depend of the annual global budget allocated by the Jerome Lejeune Foundation to the calls. Clinical projects could benefit from more funding.

• Through this call the Jerome Lejeune Foundation will also support the organization of conferences, workshops and courses. Such projects will also be reviewed by the Scientific Advisory Board.

For further details, please click on SAMPLE below.

Please know that Autumn call for proposals (submission from mid-June to early August 2019) will be exclusively dedicated to Down syndrome research with Advanced and Pilot/exploratory grants.


For the current spring call for proposals, please fill in the online application form on “JLF Call for grants from January 7 to March 5, 2019 at midnight.

Date of provisional Scientific Advisory Board decision: second fortnight of June 2019
Board of Directors final decision: early July 2019



Conseil Scientifique – Fondation Jérôme Lejeune sample
37 rue des Volontaires, 75015 Paris, France
+33 (0)1 5658 5638




Projects funded by the Jerome Lejeune Foundation

2017b cycle

15 projects funded by the Jerome Lejeune Foundation for an amount of 510,513€

France: 4; Italy: 5; Spain: 1; Israel: 1; United-Kingdom: 2; United States of America: 2

Projects focusing on Down syndrome

• Prof. Alberto Costa
Preclinical assessment of short-term sensory memory deficits in mouse models of Down syndrome: evaluation of a mismatch negativity paradigm
The Research Institute for Children’s Health (RICH)
Case Western Reserve School of Medicine
Cleveland (Ohio), USA

• Dr. JM Delabar
Etude de l’efficacité d’un analogue de l’EGCG dans des modèles murins de trisomie 21
Institut du Cerveau et de la Moelle (Brain & Spine Institute)

• Dr. Sandra Guidi
Prenatal treatment with a BDNF mimetic: a potential strategy for improving brain development in the Ts65Dn mouse model of Down syndrome
University of Bologna
Department of Biomedical and Neuromotor Sciences (DIBINEM)

• Dr. Fernando Moldenhauer
Study of the renin-angiotensin-aldosterone system and its relation to the absence of atherosclerosis in adults with Down syndrome
Fundación de Investigació Biomédica Hospital de La Princesa
Unidad de Atención a Adultos con Sindrome de Down (MIH-UPDOWN)
Madrid, Spain

• Prof. Lucio Nitsch
Therapeutic approach in Down syndrome by PGC-1alpha activation in differentiating neural cells
University of Naples Federico II
Laboratory of Cytogenetics and Cytogenomics
Department of Molecular Medicine and Medical Biotechnology

• Dr. Nicoletta Pedemonte
A drug repositioning approach for the discovery of DYRK1A regulators as a therapy for Down syndrome
Istituto di Ricovero e Cura a Carattere Scientifico “Giannina Gaslini”
Genova, Italy

• Prof. Mary Rutherford
Serial MRI to assess early structural and functional brain development in Down syndrome
Centre for Developing Brain
Department of Perinatal Imaging and Health
Kings’ College London, United-Kingdom


Projects focusing on other pathologies (syndromes such as Fragile X; Williams-Beuren; DiGeorge; Cri-du-chat…)

• Prof. Lior Appelbaum
The Allan-Herndon-Dudley syndrome: Visualizing deficient neuronal activity and examination of therapeutic applications
Bar Ilan University
Faculty of Life Sciences
Multidisciplinary Brain Research Center
Ramat Gan, Israel

• Dr. J.-V. Barnier
Caractérisation d’une nouvelle mutation d’un gène de déficience intellectuelle dans des anomalies neurodéveloppementales
Institut de Neuroscience Paris-Saclay, France

• Dr. Régine Hepp
Molecular mechanisms of a disease-causing missense mutation in the GRID1 gene associated with autosomal recessive intellectual disability
Université Pierre et Marie Curie
Institut de Biologie Paris-Seine
CNRS UMR8246/Inserm U1130/UPMC UMCR18
Paris, France

• Prof. Elizabeth Illingworth
Vitamin B12 treatment of mouse models of DiGeorge syndrome: is it effective for the brain phenotype?
Universita’ degli Studi di Salerno
Dipartimento di Chimica e Biologia
Fisciano, Italy

• Dr. Seonil Kim
Treatment of mental retardation and autistic-like characteristics in Cri du chat syndrome arising from delta-catenin haploinsufficiency
Colorado State University
Department of Biomedical Sciences
Fort Collins, USA

• Dr. Natacha Lehman
Thérapie Cognitive et Comportementale de l’anxiété dans le syndrome de Williams-Beuren
CHU Montpellier

• Dr. Viviana Trezza
The endocannabinoid system as a novel therapeutic target for Fragile X syndrome
Roma Tre University
Department of Science
Roma, Italy

• Dr. Jane Waite
Ten-year longitudinal follow-up of people with Rubinstein-Taybi syndrome: Predicting Mental Health outcomes
Aston University
School of Life and Health Sciences
Birmingham, United-Kingdom

Projects funded by the Jerome Lejeune Foundation

2018a cycle

17 projects funded by the Jerome Lejeune Foundation for an amount of 536,310€

France: 7; Italy: 3; Spain: 2; Belgium: 1; Israel: 1; United-Kingdom: 1; United States of America: 2

For your information: the project titles below are not exclusive; other project titles can be submitted.


Projects focusing on Down syndrome

Dr. Juliette GODIN
Analysis of contribution of Wdr4, a critical gene located in Abcg1-U2af1 region, to the neurodevelopmental abnormalities of Down syndrome
Institute of Genetics and Molecular and Cellular Biology (IGBMC)
Laboratory of Translational medicine and neurogenetics
67 Illkirch, France

Investigating ocular morphological differences as the possible cause of accommodation deficits in
Down’s syndrome
Aston University
Ophtalmic Research Group
School of Life and Health Sciences
Birmingham, United-Kingdom

Trisomie 21 et Leucémies Aigües Myéloïdes: Rôle du facteur de transcription RIP140
Institute of Cancer Research of Montpellier (IRCM – U1194)
34 Montpellier, France

Dr. Jamie EDGIN
Sleep as a predictor of memory performance and stability in ID syndromes
University of Arizona
Down Syndrome Research Group (DSRG)
Department of Psychology
Tucson, AZ, United States of America

Examining Recall Memory and Generalization in Children with Down Syndrome and Neurotypical Controls Matched on Developmental Age
University of California, Irvine
Department of Psychology and Social Behavior
Irvine, CA, United States of America

Patterns and causes of hospital admission, comorbidities and mortality of Spanish adults with
Down Syndrome 2005 – 2014
Hospital de La Princesa
Unit for adults with Down syndrome
Madrid, Spain

Prof. Greetje VANDE VELDE
Understanding Down syndrome as a neuro-skeletal disorder: towards integrated treatment of brain, bones and cognition
KU Leuven
Department of Imaging and Pathology
Faculty of Medicine
Leuven, Belgium

Dendritic inhibition in animal models of cognitive disabilities
Institut du Cerveau et de la Moelle (Brain & Spine Institute)
75013 Paris, France


Projects focusing on other pathologies (syndromes such as Fragile X; Williams-Beuren; DiGeorge; Cri-du-chat…)

Dr. Victoria CAMPUZANO
Molecular bases in the effectiveness of the treatment of Williams-Beuren syndrome by inhibitors of the monoacyl glycerol lipase.
Universitat Pompeu Fabra
Genetic Unit
Barcelona, Spain

Macrolide induced correction of mutations causing Rett syndrome (RTT)
Tel Aviv University
Department of Clinical Microbiology and Immunology
Tel Aviv, Israel

Dr. Barbara BARDONI
Definition of a novel therapeutic approach for Fragile X syndrome
Institute of Molecular and Cellular Pharmacology (IPMC)
06 Valbonne, France

Dr. Stéphane MARTIN
Consequences of the missense R138Q Fragile X mutation on the regulation of the FMRP function
Institute of Molecular and Cellular Pharmacology (IPMC)
06 Valbonne, France

Dr. Patrizia D’ADAMO
Direct and indirect drugs modulation of Rab39b mutant mice-related behavioral deficits
Fondazione Centro San Raffaele at Ospedale San Raffaele
Division of Neuroscience
Milano, Italy

Dr. Françoise MUSCATELLI
Critical timing of oxytocin treatment
Institut de Neurobiologie de la Méditerranée (INMED)
13 Marseille, France

Dr. Elisabetta CIANI
Innovative strategy to enhance the efficiency of brain gene therapy for the CDKL5 neurodevelopmental disorder
University of Bologna
Department of Biomedical and Neuromotor Sciences
Bologna, Italy

Dr. Jessica ROSATI
The roles of biological clock deregulation and retinoic acid signalling impairment in Smith-Magenis syndrome
Casa Sollievo della Sofferenza – Mendel Institute
Cellular Reprogramming Unit
San Giovanni Rotondo, Foggia, Italy

Congenital cREatine transporter Disorder: Insights into new Therapeutic preclinical strategies
The French Alternative Energies and Atomic Energy Commission (CEA)
Pharmacology and Immunoanalysis Unit (SPI)
91 Gif-sur-Yvette, France

Dear Future Mom

See more videos

Our newsletter

Institut medical office